The future of haemagglutinin stalk-based universal influenza vaccines

Affiliations

¹ Department of Virology, Institute of Experimental Medicine, St Petersburg 197376, Russia. Electronic address: isakova.sivak@iemspb.ru.
² Department of Virology, Institute of Experimental Medicine, St Petersburg 197376, Russia.

Comment

Irina Isakova-Sivak et al. Lancet Infect Dis. 2022 Jul.

. 2022 Jul;22(7):926-928.

doi: 10.1016/S1473-3099(22)00056-1. Epub 2022 Apr 21.

¹ Department of Virology, Institute of Experimental Medicine, St Petersburg 197376, Russia. Electronic address: isakova.sivak@iemspb.ru.
² Department of Virology, Institute of Experimental Medicine, St Petersburg 197376, Russia.

No abstract available

Conflict of interest statement

We declare no competing interests.

Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, García-Sastre A, Krammer F, Nachbagauer R, Palese P, Solórzano A, Bi D, David MP, Friel D, Innis BL, Koch J, Mallett CP, Rouxel RN, Salaun B, Vantomme V, Verheust C, Struyf F. Folschweiller N, et al. Lancet Infect Dis. 2022 Jul;22(7):1062-1075. doi: 10.1016/S1473-3099(22)00024-X. Epub 2022 Apr 21. Lancet Infect Dis. 2022. PMID: 35461522 Clinical Trial.